whitepaper

Application note: Validation of identified through AI

Posted: 1 October 2021 | | No comments yet

Targets for drug discovery can be identified with AI but require validation in vitro. Here’s how this can be done, using hiPSC technology.

AI holds great potential for target identification and assessment of compound effects. After identifying potential targets in silico, they need to be validated in physiologically relevant in vitro models. hiPSC-derived models are highly suitable for target validation, as they provide scalable and predictive solutions to assess compound efficacy and safety in high throughput. In this application note, we describe how we work together with AI companies in target validation, using hiPSC technology.












    To read this application note in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Ncardia

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Send this to a friend